Financial Review: Ignyta (RXDX) vs. Its Peers
Ignyta (NASDAQ: RXDX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Ignyta to similar companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.
Insider & Institutional Ownership
72.9% of Ignyta shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 13.1% of Ignyta shares are held by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations for Ignyta and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ignyta currently has a consensus price target of $25.25, indicating a potential upside of 62.38%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.45%. Given Ignyta’s stronger consensus rating and higher possible upside, analysts clearly believe Ignyta is more favorable than its peers.
Risk and Volatility
Ignyta has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Ignyta’s peers have a beta of 6.07, suggesting that their average share price is 507% more volatile than the S&P 500.
Valuation and Earnings
This table compares Ignyta and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ignyta Competitors||$284.28 million||$33.78 million||82.78|
Ignyta’s peers have higher revenue and earnings than Ignyta. Ignyta is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Ignyta and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ignyta Company Profile
Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.